Category: vaccines
-
The NIH just announced that a highly novel Phase 3 clinical trial of a CoV-2 RNA vaccine was launched today.
-
As reported two months ago in these pages, the vaccine that seems to have the early lead is being developed at England’s Oxford University in partnership with the pharma company AstraZeneca. On Monday, they reported encouraging results from their combination phase 1/2 study in the journal The Lancet.
-
The antibody response to the virus decays pretty quickly after the virus is cleared from an infected person’s body. The implication is that we quickly lose immunity to the virus.
-
Over the last few weeks I have repeatedly seen claims from such “experts” that since we don’t have a vaccine for the coronavirus that causes the common cold, we will never have one for the coronavirus that causes COVID-19. Therefore, they conclude that the current efforts and expense to make such a vaccine simply waste…
-
A recent Associated Press-NORC Center for Public Affairs Research poll shows that only about half of Americans would get a CoV-2 vaccine if available.
-
Because of the decline in infection rate in the UK, Oxford researchers have rolled back the expected chance of success of the vaccine to 50%.
-
My question is this: if one of these vaccines shows sufficient safety and efficacy to gain expedited approval by the FDA, would you take it?
-
Over the last couple of days, a Cambridge, Massachusetts biotech company, Moderna, that is developing a highly novel CoV-2 vax candidate in partnership with NIH, announced positive results in early stage testing of a vaccine that does not use the standard inactivated or “crippled” virus.
-
I provide a summary of what is going on. I first highlight the challenges of quickly developing a vax. Then, I give you a sample of some of these efforts and discuss some of the ingenuity that is going into these efforts around the world.
Making Sense of Medical Science (MSMS) 